ClinicalTrials.gg
CompletedNCT02641067Updated Feb 8, 2019Results posted

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

A Phase 1 interventional study of Doravirine in Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.

Enrollment
27th of 32
16 · median 26
Started
2016
the only one that year
Phase 1
25 of 32
2 open now
Registered
20th of 32
by date

Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 27th largest by enrollment, is the only one that started in 2016, is one of 25 in phase 1, and was the 20th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Renal Insufficiency by Merck & Co., Inc, or all of them as a file.
02

Study summary

This study will evaluate the effect of severe renal impairment on the pharmacokinetics of doravirine.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • is a non-smoker or moderate smoker
  • has a (BMI) ≥ 18.5 and ≤ 40.0 kg/m\^2
  • other than renal impairment, participant is judged to be in good health based on medical history, physical examination, vital signs, and laboratory safety tests
  • female informed of the risks of pregnancy, agree not to become pregnant while participating in this study. Female of must either be sexually inactive for 14 days prior to dosing and throughout the study, or uses one acceptable method
  • female of non-childbearing potential must have undergone sterilization procedures at least 6 months prior to dosing.
  • Participants with severe renal impairment only: has baseline estimated (eGFR) \< 30 mL/min/1.73m\^2

Exclusion criteria

Exclusion Criteria:

  • is mentally or legally incapacitated or has significant emotional problems
  • has a history or presence of medical or psychiatric condition or disease
  • has history or presence of alcoholism or drug abuse within the past 2 years
  • has history or presence of or idiosyncratic reaction to the study drug, any inactive ingredients, or related compounds
  • has history or presence of renal artery stenosis
  • has had a renal transplant or nephrectomy
  • has rapidly fluctuating renal function as determined by historical measurements
  • female is pregnant or lactating
  • has positive results for the urine or saliva drug and urine or breath alcohol screen at screening or check-in
  • has positive results at screening for (HIV), surface antigen (HBsAg), or virus (HCV)
  • is unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to dosing and throughout the study. Certain medications including those to treat kidney disease will be permitted. Other medications may be permitted following consultation with the Sponsor Clinical Monitor.
  • is unable to refrain from or anticipates the use of inducers of cytochrome P450 3A () or permeability glycoprotein (P-gp) transporters for at least 28 days prior to dosing and throughout the study.
  • has been on a diet incompatible with the on-study diet, within 28 days prior to dosing, and throughout the study
  • has donated blood or had significant blood loss within 56 days prior to dosing
  • has donated plasma within 7 days prior to dosing
  • has participated in another clinical trial within 28 days prior to dosing
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Severe Renal Impairment

    Participants with severe renal impairment receive a single oral dose of 100 mg doravirine

    Drug: Doravirine

  • Experimental
    Healthy Matched Control

    Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine

    Drug: Doravirine

Interventions

  • Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally

    Also known as: MK-1439, PIFELTRO

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment

  2. Plasma Concentration of Doravirine at 24 Hours Postdose (C24)

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

    Time frame: 24 hours postdose

  3. Maximum Observed Plasma Concentration (Cmax) of Doravirine

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment

  4. Area Under the Plasma Concentration Versus Time Curve From 0 Hours to the Time of Last Quantifiable Sample of Doravirine (AUC 0-last)

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment

  5. Time to Maximum Observed Plasma Concentration (Tmax) of Doravirine

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment

  6. Apparent Terminal Half-life (t1/2) of Plasma Doravirine

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment

  7. Apparent Clearance of Plasma Doravirine After Extravascular Administration (CL/F)

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment

  8. Apparent Volume of Distribution of Plasma Doravirine During the Terminal Phase (Vz/F)

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment

07

Results

Posted Feb 8, 2019

Participant flow

Participant flow — Overall Study
MilestoneSevere Renal ImpairmentHealthy Matched Controls
Started88
Completed88
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment
Reported as:
Geometric mean · μM•hr
Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine
μM•hrSevere Renal ImpairmentHealthy Matched Controls
Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine64.5 (47.4 to 87.8)45.1 (33.2 to 61.4)
Statistical analysis
  • Severe Renal Impairment vs Healthy Matched Controls · Geometric mean ratio: 1.43 · 90% CI 1.00 to 2.04
PrimaryPlasma Concentration of Doravirine at 24 Hours Postdose (C24)

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

Time frame:
24 hours postdose
Reported as:
Geometric mean · nM
Plasma Concentration of Doravirine at 24 Hours Postdose (C24)
nMSevere Renal ImpairmentHealthy Matched Controls
Plasma Concentration of Doravirine at 24 Hours Postdose (C24)943 (710 to 1250)684 (515 to 908)
Statistical analysis
  • Severe Renal Impairment vs Healthy Matched Controls · Geometric mean ratio: 1.38 · 90% CI 0.99 to 1.92
PrimaryMaximum Observed Plasma Concentration (Cmax) of Doravirine

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment
Reported as:
Geometric mean · nM
Maximum Observed Plasma Concentration (Cmax) of Doravirine
nMSevere Renal ImpairmentHealthy Matched Controls
Maximum Observed Plasma Concentration (Cmax) of Doravirine1580 (1210 to 2080)1900 (1450 to 2500)
Statistical analysis
  • Severe Renal Impairment vs Healthy Matched Controls · Geometric mean ratio: 0.83 · 90% CI 0.61 to 1.15
PrimaryArea Under the Plasma Concentration Versus Time Curve From 0 Hours to the Time of Last Quantifiable Sample of Doravirine (AUC 0-last)

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment
Reported as:
Geometric mean · μM•hr
Area Under the Plasma Concentration Versus Time Curve From 0 Hours to the Time of Last Quantifiable Sample of Doravirine (AUC 0-last)
μM•hrSevere Renal ImpairmentHealthy Matched Controls
Area Under the Plasma Concentration Versus Time Curve From 0 Hours to the Time of Last Quantifiable Sample of Doravirine (AUC 0-last)60.5 ± 56.341.0 ± 29.9
PrimaryTime to Maximum Observed Plasma Concentration (Tmax) of Doravirine

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment
Reported as:
Median · Hours
Time to Maximum Observed Plasma Concentration (Tmax) of Doravirine
HoursSevere Renal ImpairmentHealthy Matched Controls
Time to Maximum Observed Plasma Concentration (Tmax) of Doravirine2.00 (0.50 to 4.00)1.50 (0.50 to 6.00)
PrimaryApparent Terminal Half-life (t1/2) of Plasma Doravirine

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment
Reported as:
Geometric mean · Hours
Apparent Terminal Half-life (t1/2) of Plasma Doravirine
HoursSevere Renal ImpairmentHealthy Matched Controls
Apparent Terminal Half-life (t1/2) of Plasma Doravirine25.02 ± 36.416.69 ± 26.1
PrimaryApparent Clearance of Plasma Doravirine After Extravascular Administration (CL/F)

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment
Reported as:
Geometric mean · Liter/hour
Apparent Clearance of Plasma Doravirine After Extravascular Administration (CL/F)
Liter/hourSevere Renal ImpairmentHealthy Matched Controls
Apparent Clearance of Plasma Doravirine After Extravascular Administration (CL/F)3.53 ± 63.95.38 ± 32.8
PrimaryApparent Volume of Distribution of Plasma Doravirine During the Terminal Phase (Vz/F)

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution of Plasma Doravirine During the Terminal Phase (Vz/F)
LitersSevere Renal ImpairmentHealthy Matched Controls
Apparent Volume of Distribution of Plasma Doravirine During the Terminal Phase (Vz/F)127 ± 40.9129 ± 28.3

Adverse events

Collected over Up to 14 days after drug administration. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Severe Renal Impairment0/8 (0%)0/8 (0%)2/8 (25%)
Healthy Matched Control0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventSevere Renal ImpairmentHealthy Matched Control
NauseaGastrointestinal disorders1/80/8
ConjunctivitisInfections and infestations1/80/8
PhlebitisVascular disorders0/81/8

Baseline characteristics

Age, Customized
Age, Customized(Participants)Severe Renal ImpairmentHealthy Matched ControlsTotal
19 to 49 years000
50 to 59 years448
60 to 69 years448
Sex: Female, Male
Sex: Female, Male(Participants)Severe Renal ImpairmentHealthy Matched ControlsTotal
Female235
Male6511
Body Weight
Body Weight(Kilogram)Severe Renal ImpairmentHealthy Matched ControlsTotal
Mean90.86 ± 17.40990.93 ± 6.08690.89 ± 12.599
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, Preston RA, Iwamoto M, Khalilieh SG. Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00326-18. doi: 10.1128/AAC.00326-18. Print 2018 Aug. PubMed 29891610 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in May 2016, 3 months.

Results were first posted in Feb 2019, 2 years 8 months after primary completion.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2015
First posted
Dec 29, 2015
StartActual
Jan 26, 2016
Primary completionActual
May 14, 2016
CompletionActual
May 25, 2016
Results first posted
Feb 8, 2019
Last update
Feb 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02641067
Responsible party
Sponsor
First posted
Dec 29, 2015
Start date
Jan 26, 2016
Primary completion
May 14, 2016
Completion
May 25, 2016
Results posted
Feb 8, 2019
Last update
Feb 8, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doravirine

Start the discussion